Rio Pharmaceuticals

Rio Pharmaceuticals is a clinical-stage diagnostics company pioneering PET imaging tracers for neurological conditions like Alzheimer's disease and ALS. Its core technology focuses on imaging the EAAT2 transporter, a key protein involved in glutamate regulation and neuroinflammation, providing a potential early biomarker for disease pathology. The company is advancing its lead candidate, RP115, through multiple clinical trials with support from NIH and the Department of Defense, and is led by a team with deep expertise in neurology, PET imaging, and CNS drug development. As a private, pre-revenue entity, Rio aims to address a significant unmet need in neurological disease diagnostics.

Development of novel PET (positron emission tomography) radiotracers targeting specific proteins in the central nervous system. The lead platform focuses on imaging the EAAT2 transporter to quantify glutamate-related pathology and astrocyte changes in vivo.

Rio competes in the neurodiagnostic space with companies developing other PET tracers (e.g., for tau, synaptic density) and fluid biomarkers. Its specific focus on EAAT2/glutamate pathology is a differentiating niche, but it must prove clinical superiority or complementarity to existing tools. Large imaging and diagnostic firms could also be future competitors or partners.